AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Incyte Corporation

$121.47 +$20.05 (+19.77%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$123.28
Day Range
$121.42$124.35
Year Range
$81.09$132.6
Market Cap
24.62B
AVG Volume
1.68M
Trailing/Forward PE
14.94/14.22
PEG ratio
0.12
Dividend Yield
-
Next Earnings Date
2026-10-27
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
02B4B6B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q25.82B
26 Q15.36B
25 Q45.14B
25 Q34.81B
25 Q24.58B
25 Q14.41B
24 Q44.24B
24 Q34.08B
24 Q23.86B
24 Q13.77B
Net Income (USD) · TTM
0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q21.61B
26 Q11.43B
25 Q41.29B
25 Q31.19B
25 Q2870.87M
25 Q121.27M
24 Q432.62M
24 Q332.48M
24 Q297.3M
24 Q1745.44M
Operating Income (USD) · TTM
-500M0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q21.84B
26 Q11.45B
25 Q41.34B
25 Q31.26B
25 Q2970.98M
25 Q1182.04M
24 Q457.22M
24 Q3-52.88M
24 Q215.74M
24 Q1687.65M
EBITDA (USD) · TTM
01B2B3B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q22.04B
26 Q11.87B
25 Q41.76B
25 Q31.68B
25 Q21.36B
25 Q1406.83M
24 Q4408.16M
24 Q3364.8M
24 Q2440.8M
24 Q11.11B
Cash Flows (USD) · TTM
-1B01B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q21.92B
26 Q11.45B
25 Q41.35B
25 Q31.2B
25 Q2945.58M
25 Q1288.81M
24 Q4235.17M
24 Q316.8M
24 Q2-139.52M
24 Q1790.77M
EPS (USD) · TTM
0246824 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q27.85
26 Q17.08
25 Q46.41
25 Q35.97
25 Q24.4
25 Q10.32
24 Q40.27
24 Q30.14
24 Q20.36
24 Q13.3
Expenses (USD) · TTM
01B2B3B4BR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q23.61B
26 Q13.57B
25 Q43.49B
25 Q33.27B
25 Q23.32B
25 Q13.96B
24 Q43.93B
24 Q33.86B
24 Q23.61B
24 Q12.83B
Shares Outstanding (USD) · TTM
-1B01B2B3BBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
INCY Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-181M
26 Q1-226.5M
25 Q4-230.25M
25 Q3-239.81M
25 Q2-256.03M
25 Q11.74B
24 Q41.74B
24 Q31.75B
24 Q21.8B
24 Q1-196.93M
Employee Count
01K2K3K2016201720182019202020212022202320242025
INCY Employee Count by quarter
PeriodEmployee Count
20252.84K
20242.62K
20232.52K
20222.32K
20212.09K
20201.77K
20191.46K
20181.37K
20171.21K
2016980
PE Ratio
0200400600800med 18.59Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
INCY PE Ratio by quarter
PeriodPE Ratio
Sep 2615.1
Sep 2615.75
Aug 2615.46
Aug 2615.88
Aug 2614.93
Aug 2614.98
Jul 2614.85
Jul 2616.38
Jul 2616.32
Jul 2616.25
Jul 2616.27
Jun 2615.84
Jun 2613.67
Jun 2615.11
Jun 2614.25
May 2613.47
May 2613.53
May 2613.27
May 2613.72
May 2613.49
Apr 2614.52
Apr 2615.01
Apr 2614.74
Apr 2614.72
Mar 2613.86
Mar 2613.93
Mar 2614.2
Mar 2614.72
Feb 2615.54
Feb 2615.55
Feb 2615.51
Feb 2617.84
Jan 2616.47
Jan 2616.79
Jan 2617.48
Jan 2617.59
Jan 2616.7
Dec 2516.48
Dec 2516.91
Dec 2515.71
Dec 2516.88
Nov 2517.2
Nov 2516.8
Nov 2517.15
Nov 2517.45
Oct 2515.39
Oct 2520.33
Oct 2519.51
Oct 2518.67
Oct 2519.35
Sep 2518.42
Sep 2519.28
Sep 2518.51
Sep 2519.3
Aug 2518.85
Aug 2518.94
Aug 2519.36
Aug 2517.46
Aug 2516.84
Jul 25639.33
Jul 25618.02
Jul 25624.67
Jul 25623.39
Jun 25622.67
Jun 25623.48
Jun 25617.02
Jun 25626.31
May 25592.52
May 25585.14
May 25576.58
May 25537.15
May 25569.48
Apr 25350.36
Apr 25344.73
Apr 25336.79
Apr 25358.77
Mar 25358.88
Mar 25366.7
Mar 25401.88
Mar 25419.23
Feb 25435.28
Feb 25427.05
Feb 25417.04
Feb 25439.62
Jan 25439.79
Jan 25430.48
Jan 25426.57
Jan 25418.33
Jan 25412.93
Dec 24410.56
Dec 24408.24
Dec 24406.52
Dec 24450.23
Nov 24442.34
Nov 24425.32
Nov 24449.93
Nov 24494.47
Nov 24451.48
Oct 24145.91
Oct 24148.87
Free Cash Flow Yield
-2.5%0%2.5%5%7.5%10%med 5.75%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
INCY Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 267.89%
Sep 267.56%
Aug 267.71%
Aug 267.5%
Aug 267.98%
Aug 267.95%
Jul 268.02%
Jul 266.19%
Jul 266.21%
Jul 266.24%
Jul 266.23%
Jun 266.4%
Jun 267.41%
Jun 266.71%
Jun 267.11%
May 267.52%
May 267.49%
May 267.64%
May 267.38%
May 267.51%
Apr 267.25%
Apr 267.01%
Apr 267.14%
Apr 267.15%
Mar 267.6%
Mar 267.56%
Mar 267.41%
Mar 267.15%
Feb 266.77%
Feb 266.77%
Feb 266.79%
Feb 265.64%
Jan 266.11%
Jan 266%
Jan 265.76%
Jan 265.72%
Jan 266.03%
Dec 256.11%
Dec 255.96%
Dec 256.41%
Dec 255.97%
Nov 255.86%
Nov 255.99%
Nov 255.87%
Nov 255.77%
Oct 256.54%
Oct 255.34%
Oct 255.57%
Oct 255.82%
Oct 255.61%
Sep 255.89%
Sep 255.63%
Sep 255.87%
Sep 255.63%
Aug 255.76%
Aug 255.73%
Aug 255.61%
Aug 256.22%
Aug 256.45%
Jul 252.12%
Jul 252.2%
Jul 252.17%
Jul 252.18%
Jun 252.18%
Jun 252.18%
Jun 252.2%
Jun 252.17%
May 252.29%
May 252.32%
May 252.35%
May 252.53%
May 252.38%
Apr 252.06%
Apr 252.09%
Apr 252.14%
Apr 252.01%
Mar 252.01%
Mar 251.97%
Mar 251.79%
Mar 251.72%
Feb 251.66%
Feb 251.69%
Feb 251.73%
Feb 250.12%
Jan 250.12%
Jan 250.12%
Jan 250.12%
Jan 250.12%
Jan 250.13%
Dec 240.13%
Dec 240.13%
Dec 240.13%
Dec 240.11%
Nov 240.12%
Nov 240.12%
Nov 240.11%
Nov 240.1%
Nov 240.11%
Oct 24-0.98%
Oct 24-0.96%
Price to Sales
2.533.544.5med 3.6Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
INCY Price to Sales by quarter
PeriodPrice to Sales
Sep 264.18
Sep 264.36
Aug 264.28
Aug 264.4
Aug 264.14
Aug 264.15
Jul 264.12
Jul 264.38
Jul 264.36
Jul 264.34
Jul 264.35
Jun 264.23
Jun 263.65
Jun 264.04
Jun 263.81
May 263.6
May 263.61
May 263.54
May 263.66
May 263.6
Apr 263.63
Apr 263.76
Apr 263.69
Apr 263.68
Mar 263.47
Mar 263.49
Mar 263.55
Mar 263.68
Feb 263.89
Feb 263.89
Feb 263.88
Feb 264.41
Jan 264.07
Jan 264.15
Jan 264.32
Jan 264.34
Jan 264.12
Dec 254.07
Dec 254.17
Dec 253.88
Dec 254.17
Nov 254.25
Nov 254.15
Nov 254.23
Nov 254.31
Oct 253.8
Oct 253.86
Oct 253.71
Oct 253.55
Oct 253.67
Sep 253.5
Sep 253.66
Sep 253.52
Sep 253.67
Aug 253.58
Aug 253.6
Aug 253.68
Aug 253.32
Aug 253.2
Jul 253.08
Jul 252.98
Jul 253.01
Jul 253
Jun 253
Jun 253
Jun 252.97
Jun 253.02
May 252.86
May 252.82
May 252.78
May 252.59
May 252.74
Apr 252.69
Apr 252.65
Apr 252.59
Apr 252.76
Mar 252.76
Mar 252.82
Mar 253.09
Mar 253.22
Feb 253.35
Feb 253.28
Feb 253.21
Feb 253.5
Jan 253.5
Jan 253.43
Jan 253.4
Jan 253.33
Jan 253.29
Dec 243.27
Dec 243.25
Dec 243.24
Dec 243.59
Nov 243.53
Nov 243.39
Nov 243.59
Nov 243.94
Nov 243.6
Oct 243.68
Oct 243.76
EV/EBITDA
010203040med 10.62Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
INCY EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 269.72
Sep 2610.24
Aug 2610
Aug 2610.34
Aug 269.59
Aug 269.63
Jul 269.53
Jul 2610.41
Jul 2610.36
Jul 2610.31
Jul 2610.32
Jun 269.99
Jun 268.34
Jun 269.44
Jun 268.78
May 268.18
May 268.22
May 268.03
May 268.37
May 268.2
Apr 268.62
Apr 268.98
Apr 268.78
Apr 268.77
Mar 268.13
Mar 268.19
Mar 268.39
Mar 268.77
Feb 269.36
Feb 269.37
Feb 269.35
Feb 2610.89
Jan 269.92
Jan 2610.14
Jan 2610.63
Jan 2610.71
Jan 2610.08
Dec 259.93
Dec 2510.23
Dec 259.38
Dec 2510.21
Nov 2510.43
Nov 2510.15
Nov 2510.4
Nov 2510.61
Oct 259.15
Oct 2511.31
Oct 2510.78
Oct 2510.24
Oct 2510.67
Sep 2510.08
Sep 2510.63
Sep 2510.14
Sep 2510.64
Aug 2510.35
Aug 2510.42
Aug 2510.68
Aug 259.46
Aug 259.06
Jul 2527.61
Jul 2526.5
Jul 2526.84
Jul 2526.78
Jun 2526.74
Jun 2526.78
Jun 2526.44
Jun 2526.93
May 2525.16
May 2524.78
May 2524.33
May 2522.27
May 2523.96
Apr 2522.82
Apr 2522.37
Apr 2521.73
Apr 2523.49
Mar 2523.5
Mar 2524.12
Mar 2526.93
Mar 2528.32
Feb 2529.6
Feb 2528.94
Feb 2528.14
Feb 2534.38
Jan 2534.39
Jan 2533.57
Jan 2533.22
Jan 2532.48
Jan 2532
Dec 2431.79
Dec 2431.59
Dec 2431.43
Dec 2435.32
Nov 2434.62
Nov 2433.11
Nov 2435.3
Nov 2439.26
Nov 2435.43
Oct 2428.85
Oct 2429.5
Price/Operating Cashflow
050100150200med 16.59Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
INCY Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2612.29
Sep 2612.83
Aug 2612.59
Aug 2612.94
Aug 2612.16
Aug 2612.2
Jul 2612.1
Jul 2615.46
Jul 2615.41
Jul 2615.34
Jul 2615.36
Jun 2614.95
Jun 2612.91
Jun 2614.26
Jun 2613.46
May 2612.71
May 2612.77
May 2612.53
May 2612.95
May 2612.74
Apr 2613.22
Apr 2613.66
Apr 2613.42
Apr 2613.4
Mar 2612.61
Mar 2612.68
Mar 2612.93
Mar 2613.4
Feb 2614.15
Feb 2614.15
Feb 2614.12
Feb 2616.95
Jan 2615.65
Jan 2615.95
Jan 2616.61
Jan 2616.71
Jan 2615.86
Dec 2515.65
Dec 2516.06
Dec 2514.92
Dec 2516.03
Nov 2516.33
Nov 2515.96
Nov 2516.28
Nov 2516.57
Oct 2514.62
Oct 2517.66
Oct 2516.94
Oct 2516.21
Oct 2516.8
Sep 2516
Sep 2516.74
Sep 2516.07
Sep 2516.76
Aug 2516.37
Aug 2516.45
Aug 2516.81
Aug 2515.16
Aug 2514.62
Jul 2535.54
Jul 2534.36
Jul 2534.73
Jul 2534.66
Jun 2534.62
Jun 2534.66
Jun 2534.3
Jun 2534.82
May 2532.94
May 2532.53
May 2532.05
May 2529.86
May 2531.66
Apr 2534.08
Apr 2533.53
Apr 2532.76
Apr 2534.89
Mar 2534.91
Mar 2535.67
Mar 2539.09
Mar 2540.77
Feb 2542.34
Feb 2541.53
Feb 2540.56
Feb 25140.2
Jan 25140.26
Jan 25137.29
Jan 25136.04
Jan 25133.41
Jan 25131.69
Dec 24130.94
Dec 24130.2
Dec 24129.65
Dec 24143.59
Nov 24141.07
Nov 24135.65
Nov 24143.5
Nov 24157.7
Nov 24143.99
Jul 2418.76
Jul 2418.01
Price to Book
33.544.555.5med 3.93Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
INCY Price to Book by quarter
PeriodPrice to Book
Sep 263.84
Sep 264
Aug 263.93
Aug 264.04
Aug 263.8
Aug 263.81
Jul 263.77
Jul 264.22
Jul 264.21
Jul 264.19
Jul 264.2
Jun 264.08
Jun 263.53
Jun 263.9
Jun 263.68
May 263.47
May 263.49
May 263.42
May 263.54
May 263.48
Apr 263.62
Apr 263.74
Apr 263.67
Apr 263.67
Mar 263.45
Mar 263.47
Mar 263.54
Mar 263.67
Feb 263.87
Feb 263.87
Feb 263.86
Feb 264.56
Jan 264.21
Jan 264.29
Jan 264.47
Jan 264.5
Jan 264.27
Dec 254.21
Dec 254.32
Dec 254.01
Dec 254.31
Nov 254.39
Nov 254.29
Nov 254.38
Nov 254.46
Oct 253.93
Oct 254.25
Oct 254.07
Oct 253.9
Oct 254.04
Sep 253.85
Sep 254.02
Sep 253.87
Sep 254.03
Aug 253.94
Aug 253.96
Aug 254.04
Aug 253.65
Aug 253.52
Jul 253.71
Jul 253.58
Jul 253.62
Jul 253.62
Jun 253.61
Jun 253.62
Jun 253.58
Jun 253.63
May 253.44
May 253.39
May 253.34
May 253.12
May 253.3
Apr 253.31
Apr 253.26
Apr 253.19
Apr 253.39
Mar 253.4
Mar 253.47
Mar 253.8
Mar 253.97
Feb 254.12
Feb 254.04
Feb 253.95
Feb 254.5
Jan 254.5
Jan 254.41
Jan 254.37
Jan 254.28
Jan 254.23
Dec 244.21
Dec 244.18
Dec 244.16
Dec 244.61
Nov 244.53
Nov 244.36
Nov 244.61
Nov 245.06
Nov 244.62
Oct 244.74
Oct 244.83
Incyte Corporation
INCY
Stockpicker

Video analysis: INCY

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: INCY

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

seekingalpha.com · 10 Sep 2026

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

seekingalpha.com · 9 Sep 2026

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?

zacks.com · 9 Sep 2026

Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?

Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Growth segment of the US equity market.

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

seekingalpha.com · 2 Sep 2026

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.

84,502 Shares in Incyte Corporation $INCY Bought by Beacon Pointe Advisors LLC

defenseworld.net · 29 Aug 2026

84,502 Shares in Incyte Corporation $INCY Bought by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC bought a new position in Incyte Corporation (NASDAQ: INCY) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 84,502 shares of the biopharmaceutical company's stock, valued at approximately $9,579,000. Several other large investors have also recently bought and

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

globenewswire.com · 27 Aug 2026

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.

Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?

zacks.com · 27 Aug 2026

Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More

247wallst.com · 20 Aug 2026

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More

Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck and Co., Shopify, TJX Companies, and More

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.